Lilly’s $7.8B Centessa Bet Signals a New M&A Playbook: Buy the Mechanism, Not the Molecule
Lilly's $7.8B Centessa acquisition, approved by UK High Court on June 22, reveals Big Pharma's new M&A logic: own...
biopharma M&A
Biogen’s Immunology Buying Spree Reveals a Strategy the Neurology Playbook Can No Longer Support
Biogen's $1B RayThera deal is its second major immunology acquisition in two years. A pipeline pivot this deliberate signals...
Jupiter Neurosciences’ $100M ALA-002 Bet Is a Regulatory Arbitrage Play, Not a Science Story
Jupiter Neurosciences (JUNS) just licensed ALA-002, a Novel Chemical Entity MDMA, for $100M+—here's why the NCE status matters more...
The Junk-to-Grade Playbook: Why Teva’s Upgrade Is a Signal, Not a Story
Teva's BBB- upgrade from Fitch on May 18 signals a new M&A-ready posture—and reveals a playbook other over-leveraged pharma...
China Biotech Deal Volume Surged 81% as Western Pharma Doubles Down
A BIO China panel based on anonymous survey data from BD heads and senior dealmakers revealed that nearly 80%...